India Set to Revolutionize Obesity Treatments with Affordable Generics

Wed Mar 18 2026 20:07:08 GMT+0000 (Coordinated Universal Time)

The expiration of the semaglutide patent in India opens doors for the domestic pharmaceutical industry to create low-cost versions of popular weight-loss medications, potentially transforming access to treatments for millions struggling with obesity.

As the patent for semaglutide—the active ingredient in Novo Nordisk's sought-after obesity medications—expires in India, the pharmaceutical landscape is gearing up for significant changes. Domestic manufacturers are expected to introduce generics at prices significantly lower than the current treatments, making these drugs accessible to a broader population. This move could dramatically alter the obesity treatment paradigm in India and beyond as competition drives prices down and demands for effective solutions grow amid rising obesity rates.

India Set to Revolutionize Obesity Treatments with Affordable Generics

India could soon get a lot thinner - at least in theory.

On Friday, the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country.

This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.

Investment bank Jefferies has called it a potential magic-pill moment for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.

Analysts expect around 50 branded semaglutide generics to enter the market within months, a familiar pattern in India's fiercely competitive pharmaceutical industry. When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.

India's pharmaceutical industry, currently worth about $60bn, is expected to double by 2030. Much of it is built on generics - a manufacturing muscle that now sets the stage for fierce competition over semaglutide.

Originally developed to treat diabetes, these drugs are now being hailed as game changers for weight loss, offering results that few previous treatments could match. Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.

By boosting insulin release and slowing the emptying of the stomach, these drugs make people feel full sooner and stay full longer. They have become some of the most sought-after weight-loss treatments in the world.

Several Indian drugmakers are already preparing to make the move. According to Sheetal Sapale, vice-president at research firm Pharmarack, major firms including Cipla, Sun Pharma, Dr Reddy's Laboratories, Biocon, Natco, Zydus, and Mankind Pharma are readying branded generics, with many more likely to follow. Prices are expected to fall sharply.

Current monthly treatment costs are steep: Ozempic typically sells for 8,800 - 11,000 rupees ($95-$119), while Wegovy can cost 10,000-16,000 rupees ($108-$173). Sapale expects generic competition to push that down to roughly 3,000-5,000 rupees ($36-54) per month.

India's anti-obesity drug sector has already grown rapidly, from roughly $16m in 2021 to close to $100m. Demand accelerated after the launch of Rybelsus in 2022, the first oral version of semaglutide.

India already has more than 77 million people with type-2 diabetes and one of the world's largest populations of overweight adults. Urban lifestyles, carbohydrate-heavy diets, and sedentary habits continue to drive these conditions.

However, dangers may accompany the benefits; health professionals warn that quality must be managed as cheaper generics flood the market. This urgent necessity for regulation is echoed by various specialists who express cautious optimism about the forthcoming changes in the market.

For regulators and doctors alike, the coming months may test whether India can balance affordability with oversight. The ability to offer these medications broadly could signify a transformative moment in the fight against obesity and diabetes in India and potentially influence global practices in this sector.